New drug cocktail aims to shrink Hard-to-Treat lung tumors
NCT ID NCT07670013
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of two drugs—lucankizumab and goleirex—as a first treatment for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The study will enroll 43 participants to see if the combo shrinks tumors and how safe it is. If it works, it could provide a new option for this hard-to-treat cancer type.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lucankizumab (SKB264) plus goleirex (KRAS G12C inhibitor)
What this could lead to
If successful, this combination could offer a new first-line treatment option that shrinks tumors and delays progression for people with a specific type of advanced lung cancer.
What could go wrong
This is a small, early-phase trial with only 43 participants, so results may not apply to everyone. The combination may cause side effects, and it is not yet known if it improves survival compared to existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
2nd Affiliated Hospital, School of Medicine
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••